-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx says finger-prick sepsis test tracks lab Nu.Q NETs assay in clinical study

PUBT·08/12/2026 12:21:15
Listen to the news
VolitionRx says finger-prick sepsis test tracks lab Nu.Q NETs assay in clinical study
  • VolitionRx reported clinical study results showing its finger-prick, point-of-care sepsis test aligned with its established lab assay.
  • Findings support rapid bedside identification of higher-risk sepsis patients, reducing reliance on centralized laboratories.
  • Decentralized testing could broaden commercial reach, with the company targeting a $3.8 billion global NETosis-testing market.
  • Management flagged expansion potential in lower-income countries with limited lab infrastructure, citing roughly 166 million annual sepsis cases worldwide.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN24762) on August 12, 2026, and is solely responsible for the information contained therein.